Defibrotide in the prevention and treatment of veno‐occlusive disease in autologous and allogeneic stem cell transplantation in children

Abstract

VOD incidence and severity was reduced in the defibrotide group which suggests that defibrotide might be effective in preventing and treating VOD. Sufficiently powered randomised trials are now required to definitively test the role of defibrotide in this setting.